These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15504834)

  • 21. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.
    Vourvahis M; Wang R; Gruener DM; Bruce RD; Haider S; Tawadrous M
    Drug Alcohol Depend; 2012 Nov; 126(1-2):183-8. PubMed ID: 22682979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methadone and anti-HIV drugs.
    Fornataro K
    Body Posit; 1999 May; 12(5):13. PubMed ID: 11366305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.
    Clarke SM; Mulcahy FM; Tjia J; Reynolds HE; Gibbons SE; Barry MG; Back DJ
    Br J Clin Pharmacol; 2001 Mar; 51(3):213-7. PubMed ID: 11298066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?
    George R; Haywood A; Good P; Hennig S; Khan S; Norris R; Hardy J
    Clin Ther; 2017 Sep; 39(9):1840-1848. PubMed ID: 28827023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methadone withdrawal symptoms with nevirapine and efavirenz.
    Pinzani V; Faucherre V; Peyriere H; Blayac JP
    Ann Pharmacother; 2000 Mar; 34(3):405-7. PubMed ID: 10917395
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
    Khalilieh S; Yee KL; Sanchez RI; Vaynshteyn K; Fan L; Searle S; Bouhajib M; Iwamoto M
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):151-161. PubMed ID: 31120195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silibinin affects the pharmacokinetics of methadone in rats.
    Pan PP; Wang J; Luo J; Wang SH; Zhou YF; Chen SZ; Du Z
    Drug Test Anal; 2018 Mar; 10(3):557-561. PubMed ID: 28643437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program.
    Torrens M; Castillo C; San L; del Moral E; González ML; de la Torre R
    Drug Alcohol Depend; 1998 Nov; 52(3):193-200. PubMed ID: 9839145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients.
    Leimanis E; Best BM; Atayee RS; Pesce AJ
    J Anal Toxicol; 2012 May; 36(4):239-49. PubMed ID: 22511698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
    Shahar E; Krivoy N; Weltfriend S; Pollack S
    Jpn J Infect Dis; 2004 Oct; 57(5):212-3. PubMed ID: 15507779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    Mustafa S; Yusuf WN; Woillard JB; Choon TS; Hassan NB
    Eur J Clin Pharmacol; 2016 Jul; 72(7):831-8. PubMed ID: 27025609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tolerability of efavirenz after nevirapine-related adverse events.
    Clarke S; Harrington P; Barry M; Mulcahy F
    Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
    Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics.
    Eap CB; Finkbeiner T; Gastpar M; Scherbaum N; Powell K; Baumann P
    Eur J Clin Pharmacol; 1996; 50(5):385-9. PubMed ID: 8839661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and risk factors for nevirapine-associated rash.
    de Maat MM; ter Heine R; Mulder JW; Meenhorst PL; Mairuhu AT; van Gorp EC; Huitema AD; Beijnen JH
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):457-62. PubMed ID: 12920493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing.
    Begg EJ; Malpas TJ; Hackett LP; Ilett KF
    Br J Clin Pharmacol; 2001 Dec; 52(6):681-5. PubMed ID: 11736879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.